• DOI:10.1097/01720610-200711000-00005
Corpus ID: 25472128

The Endocannabinoid System: Novel Pathway for Cardiometabolic Risk‐Factor Reduction

@article{Woods2007TheES,
  title={The Endocannabinoid System: Novel Pathway for Cardiometabolic Risk‐Factor Reduction},
  author={S. Woods},
  journal={Journal of the American Academy of Physician Assistants},
  year={2007},
  volume={20},
  pages={7–10}
}

S. Woods

Published 2007

Medicine

Journal of the American Academy of Physician Assistants

Although rimonabant has been approved for use in several countries, the Food and Drug Administration has expressed concern about the potential for adverse neurologic and psychiatric effects, considering the widespread distribution of CB1 receptors in the brain. While more research is clearly needed, the clinical evidence shows that CB1-receptor blockade with rimonabant improves multiple cardiovascular and metabolic variables, including body weight and waist circumference, HDL-C, triglycerides… CONTINUE READING

View on Wolters Kluwer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed